Study Duration definition

Study Duration means an indication of the standard length of time it takes to complete a Programme, as set out in our postgraduate tuition fees pages on the University of Liverpool Online Programmes Website; Kaplan means Xxxxxx Open Learning (Liverpool) Limited, an affiliate college of the University of Liverpool, incorporated and registered in England and Wales with company number 11979168, whose registered office is Palace House, 0 Xxxxxxxxx Xx, Xxxxxx XX0 0XX; Maximum Period of Registration means the maximum period in which your Programme must be completed. This can be found in our Code of Practice on Assessment; Net Tuition Fees means the tuition fees payable by you to study on your chosen Programme after deduction of approved discounts and/or scholarships (if any), as shown in your offer letter; Programme in these terms and conditions means a programme of study delivered online in partnership between the University and Kaplan, which leads to an award of the University; Start Date means the date on which the Programme you have accepted a place on commences; University means the University of Liverpool, an exempt charity, incorporated and registered in England and Wales as a Royal Charter Company with company number RC000660, whose address is the Foundation Building, 000 Xxxxxxxx Xxxx, Liverpool L69 7ZX; and University of Liverpool Online Programmes Website means the web pages at xxxx://xxxxxx.xxxxxxxxx.xx.xx
Sample 1Sample 2Sample 3
Study Duration. Adverse events will be collected for the duration of all studies. Study completion (closure) is defined as later of: - the last dose of the study medication, - the last visit by the subject or patient or, - the last subject or patient contact (e.g., phone contact) with the Investigator or designee as defined in the protocol. SAEs that occur within thirty (30) days after this closure must be reported. For survival studies, only deaths (not all serious AEs), that occur after the thirty (30) day period (study completion for each patient) need be reported.
Sample 1Sample 2
Study Duration. Given two months for recruitment and with two study treatments provided 30 days apart, the anticipated study duration is six months. Table of Contents Signature Page Sponsor Contact Information ii Sponsor Agreement
Sample 1

Examples of Study Duration in a sentence

  • Study Duration 1 Year Assessment Tools Ankle Brachial Index HbA1c Monofilament test for neuropathy Photograph E-Z Graph Wound Assessment System Sf-36v2 Health Survey Primary Endpoint Proportion of subjects who have a closed wound at or before 12 weeks after the index procedure.

  • Route: Continuous exposure via diffusion from the Chemoplaque Study Duration: • Up to 3 years to complete accrual, based on historical data indicating 25 eligible patients at SickKids from May 2015 to October 2018 • 5 years follow-up per patient Participant Duration in the Study and Off- study Data Collection: Each participant included in the study will be treated with the Chemoplaque for 6 weeks; evaluation continues for toxicity and tumour activity for 3 weeks following the removal of the Chemoplaque.

  • Clinical trial characteristics between 1999 and 2012 were analyzed based on Year Received, charting trends for Cost/Patient, Total Cost, Number of Patients, Study Duration, and Average Age.

  • Year 1st Received… 30 Figure 4: Number of Participants vs Year 1st Received… 31 Figure 5: Study Duration (months) vs Year 1st Received… 31 INTRODUCTION Foreword: Clinical Trial Significance Randomized clinical trials provide support for robust research and serve as a gold standard in the evaluation of safety and potential efficacy for treatment drugs, devices, and strategies (Xxxxxxxxxx et al., 2008).

  • Sites: 1 Anticipated Study Duration: 3 months Participant Duration: Single visit (1 day) 4 Background Information‌ The Collaboration Live Clinical Study is intended to evaluate the performance and safety of the Collaboration Live software in a clinical setting and will enroll 30 patients scheduled for routine OB/GYN ultrasound exams.

  • Table 6: Patient Descriptions Accounting for Outliers Summary Data Number of Studies 43 Total Number of Patients 19,306 Total Cost of All Studies $483,338,477 Average Study Duration (Months) 58.53 Average Cost per Study $11,240,430 Average # Patients/Study 449 Average Age 57.86 Cost/Patient (Excluding ^ patient Outlier) $25,035 Range of Years 1999-2012 RESULT TRENDS: Results suggest that over time, the cost of conducting cardiovascular clinical trials is increasing per patient.

  • Study Duration: Approximately eight (8) months Participant Duration: The study duration for each participant is up to approximately five (5) months (up to four [4] weeks for Screening, a single day of Treatment, and up to 16 weeks of Follow-up).


More Definitions of Study Duration

Study Duration. The total study duration for [**].
Sample 1

Related to Study Duration

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase III Clinical Study means a human clinical study of a product on a sufficient number of subjects that is designed to establish that such product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such product, as described in 21 C.F.R. 312.21(c). 1.185. [***] 1.186. [***]

  • Study Site means the location(s) under the control of the Institution where the Study is actually conducted as set out in Schedule 1.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Dose is a generic term that means absorbed dose, dose equivalent, effective dose equivalent, committed dose equivalent, committed effective dose equivalent, total organ dose equivalent, or total effective dose equivalent. For purposes of these regulations, "radiation dose" is an equivalent term.

  • Study Subject an individual who participates in the Study, either as a recipient of the Investigational Product (defined below) or as a control. Subjekt studie: jednotlivec, který se účastní Studie, buď jakožto příjemce Hodnoceného léčiva (ve smyslu níže uvedené definice) nebo jako kontrolní subjekt.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • Prosthesis means an artificial substitute for a missing body part.